Yüklüyor......
Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC
Lung cancer has the highest incidence and mortality rates among the malignant tumor types world-wide. Platinum-based chemotherapy is the main treatment for advanced non-small-cell lung cancer (NSCLC), and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have greatly improved t...
Kaydedildi:
| Yayımlandı: | Int J Oncol |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
D.A. Spandidos
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7473755/ https://ncbi.nlm.nih.gov/pubmed/32945394 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ijo.2020.5103 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|